US Stock Insider Trading | CDT disclosed one insider trading transaction on February 23

K-LinePoet · 2026-02-26T10:28:12+00:00

CDT disclosed that director Farley Chele Chiavacci purchased 10,600 shares in an insider transaction on February 19, 2026. Meanwhile, the company collaborates with life sciences companies through a unique business model to promote the development of new therapies.

K-LinePoet

2026-02-26 10:28:12

Abstract generation in progress

On February 23, 2026, CDT (CDT) disclosed a recent insider transaction. Director Farley Chele Chiavacci purchased 10,600 shares on February 19, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Director	Farley Chele Chiavacci	February 19, 2026	Buy	10,600	1.04	11,000
December 22, 2025	Shareholder with >10% stake	Regan Andrew	December 8, 2025	Buy	224,800	1.79	402,400
September 22, 2025	Shareholder with >10% stake	Regan Andrew	September 19, 2025	Buy	1,120,000	0.69	768,700
June 13, 2025	Shareholder with >10% stake	Regan Andrew	June 3, 2025	Buy	154,800	3.23	500,000
April 17, 2025	Director	Charles Faith L.	April 16, 2025	Buy	115,200	0.87	100,000
April 1, 2025	Director	Charles Faith L., Farley Chele Chiavacci, Fry Simon Jeremy, Lewis-Hall Freda C	March 30, 2025	Buy	155,600	0.89	138,500
November 20, 2024	Director	Charles Faith L., Farley Chele Chiavacci, Lewis-Hall Freda C	November 18, 2024	Buy	1,003,800	0.09	92,200
October 7, 2024	Shareholder with >10% stake	Nirland Ltd	October 7, 2024	Sell	939,000	0.10	96,500
October 3, 2024	Shareholder with >10% stake	Nirland Ltd	October 3, 2024	Sell	1,500,000	0.10	156,500
October 4, 2024	Shareholder with >10% stake	Nirland Ltd	October 4, 2024	Sell	1,369,000	0.10	140,500

【Company Information】

CDT Equity Inc. is registered in Delaware. Conduit has developed a unique business model that enables it to act as a pipeline bringing clinical assets from pharmaceutical companies and developing new therapies for patients. The company’s new approach addresses unmet medical needs and commercializes its products through cutting-edge solid-state technology and collaborations with life science companies, extending the company’s intellectual property portfolio.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.